Compare Gilead Sciences, Inc. (GILD) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Quantumscape Corp — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Quantumscape Corp trades at $4.65 (market cap $2.82B). The key difference: Gilead Sciences, Inc. is far larger — about 64.7× Quantumscape Corp's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Quantumscape Corp for 37 Days on average.
| GILD | QS | |
|---|---|---|
Market Cap | $182.40B | $2.82B |
Volume | 4,469,821 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $18.44 |
52-Week Low | $116.74 | $4.52 |
Typical Hold Time | 111 Days | 37 Days |
Enterprise Value | $205.46B | $2.03B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
QuantumScape (QS) trades at $4.52, down 2.8% today, reflecting ongoing investor skepticism about the solid-state battery developer's commercial timeline. The company remains pre-revenue with negative $435M net income in 2025, though it has beaten EPS estimates in two of the last three quarters. Technical indicators show bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautious with 73% hold ratings.
QS faces significant execution risk with commercialization not expected until 2029, creating substantial uncertainty for investors. The stock trades at a discount to the $10.35 consensus target, offering potential upside if technology milestones are met, but requires high risk tolerance given the lengthy path to profitability and intense competition in battery technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
